Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial

Core Insights - Anixa Biosciences is conducting a Phase 1 clinical trial for its CAR-T therapy targeting recurrent ovarian cancer, with the second patient in the fourth dose cohort treated successfully [1][3] - The fourth cohort is receiving a dose of three million CAR-positive cells per kilogram, a 30-fold increase from the initial dose, with no dose-limiting toxicities observed to date [2][4] - The CAR-T program targets the follicle-stimulating hormone receptor (FSHR), which is selectively expressed on ovarian cells and certain cancer cells, indicating a potential for targeted therapy [3][4] Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a proprietary CAR-T program developed in collaboration with Moffitt Cancer Center [5] - The CAR-T technology is differentiated by its use of the natural ligand of the FSHR receptor, FSH, which binds directly to tumor cells rather than using an antibody fragment [5] - Anixa's vaccine portfolio includes collaborations with Cleveland Clinic to develop vaccines for breast and ovarian cancer, as well as other cancers, focusing on immunizing against specific proteins expressed in cancer [5]